Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Multifunctional Gold Nanostars for Cancer Theranostics
This thesis presents the development of theranostic gold nanostars (GNS) for multimodality cancer imaging and therapy. Furthermore, it demonstrates that a novel two-pronged treatment, combining immune-checkpoint inhibition and GNS-mediated photothermal nanotherapy, can not only eradicate primary treated tumors but also trigger immune responses to treat distant untreated tumors in a mouse animal model. Cancer has become a significant threat to human health with more than eight million deaths each year, and novel methods for cancer management to improve patients’ overall survival are urgently needed. The developed multifunctional GNS nanoprobe with tip-enhanced plasmonics in the near-infrare...
Encyclopedia of Cancer Prevention and Management: Volume V (Advances in Cancer Management)
This book provides an overview of current knowledge and discusses some of the unanswered questions at the forefront of the research in cancer management. Cancer is now the most frequent reason of death in the world. Nowadays, because of early identificati
ICRDB Cancergram
None
mTOR Inhibition for Cancer Therapy: Past, Present and Future
This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compounds currently under evaluation.
ABC of Lung Cancer
Lung Cancer is the most common cause of cancer death and cancer symptoms. The ABC of Lung Cancer is a much needed reference for those treating and caring for patients with lung cancer such as primary care doctors, specialist cancer nurses, junior doctors, nurses, physiotherapists, radiographers and other health care professionals. This new title in the ABC series covers the epidemiology and diagnosis of lung cancer, focusing particularly on primary care issues such as what symptoms require urgent investigation, and when to refer to a specialist. This is a practical guide for all those involved in the care of the lung cancer patient, as well as patients and their families and carers.
Molecular Pathology of Breast Cancer
The complex landscape of breast cancer requires distinct strategies for the management of various molecular subtypes of this disease. Rapid advances in the field of molecular biology have been bewildering for those involved in its study and management. “Molecular Pathology of Breast Cancer” aims to close this knowledge gap by discussing comprehensively the evolution, biological basis and clinical applications with a focus on the “what, when, and how” of the most significant molecular markers known to date. These markers are evaluated in the context of genomic, transcriptomic and proteomic profiles, which is integral to the practice of precision medicine. The application of next gener...
Pancreatic Cancer
American Cancer Society Atlas of Clinical Oncology ACS Pancreatic Cancer At present, there are approximately 28,300 new cases of pancreatic cancer in the United States. It is the fourth leading cause of cancer death in men and women. Approximately 2 out of 10 patients with cancer of the pancreas will live at least one year after ......
Free of 'Incurable' Cancer
Diagnosed with incurable cancer in 2009 with a maximum six-year life expectancy, the author chronicles her journey through traditional and alternative treatments to complete remission. Without rejecting traditional treatment (i.e., chemo or radio therapies), she refused to be an object to be treated by others. Though initially terrified, she was able to move on, insisting on knowing what was going on and why. This required research, adventure (trips to other countries), sadness, humour, serenity, and some very surprising "alternatives." These include self-hypnosis, determining the emotional causes of my lymphoma, working with a medium, and the essential need for laughter and hope. Her roadmap could be described as interactive, since newly-diagnosed cancer patients overwhelmed by their situation can adapt her approach to their lives.
New Drugs in Cancer Chemotherapy
The Analog Potential in Cancer Chemotherapy in the United States and Japan S. K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing ...
Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death in the United States and has the worst mortality rate of any cancer. It is very likely that the number of deaths from pancreatic cancer each year will surpass the number of deaths from other more common cancers, such as breast cancer. This volume is dedicated to helping curb these daunting statistics by providing a knowledge base for clinicians and scientists who want to make a difference for patients both now and in the future. Edited by an eminent team consisting of a medical oncologist, a cancer surgeon and a pathologist, with contributions from over 100 world-class experts in the field, the book includes 54 state of the art chapters -- all with full color illustrations. Special "Commentaries," written by world authorities on the subject, provide expert analysis and counterpoint to selected topics.
